The Addition Expands Dotmatics Flow Cytometry Solutions
Covering the End-to-End Workflow From Experimental Design to
Downstream Data Analysis
BOSTON, July 30,
2024 /PRNewswire/ -- Dotmatics, a leader in
R&D scientific software connecting science, data, and
decision-making, today announced the successful acquisition of
EasyPanel, a high-growth company specializing in flow cytometry
panel design software. The acquisition marks another milestone for
Dotmatics, expanding the breadth and depth of its flow cytometry
solutions. EasyPanel is the 14th acquisition by Dotmatics in its
work to provide scientists with best-in-class scientific software
and a comprehensive scientific intelligence platform for multimodal
scientific research & development.
EasyPanel offers an innovative flow cytometry product that
is highly complementary to Dotmatics' existing capabilities with
OMIQ and FCS Express. Its intelligent and automated flow cytometry
panel designer utilizes a proprietary algorithm to suggest
optimized panels based on a customer's test environment for
improved experimental impact. Users can also manually edit the
suggested panels, receive smart recommendations for gating
strategies, and automatically manage their antibody inventory.
Flow cytometry panel design refers to the process of selecting
and combining specific fluorophores and antibodies to analyze
multiple parameters (such as cell surface markers, intracellular
proteins, and viability indicators) simultaneously on individual
cells within a biological sample.
It is the initial step in the flow cytometry phenotyping
process, occurring before panel preparation in the wet lab, data
acquisition on a flow cytometer, and subsequent analysis using
software like FCS Express and OMIQ.
EasyPanel gives Dotmatics a more comprehensive approach to flow
cytometry by adding panel design capabilities which will greatly
enhance its current offerings, enabling Dotmatics to provide even
more robust solutions to its customers.
"Our flow cytometry customers are working with increasingly
sophisticated panels for high dimensional assays, which in turn are
generating large amounts of complex data for subsequent analysis,"
said Brett Ammundsen, President of
Bioinformatics at Dotmatics. "EasyPanel's panel design permits
R&D scientists to generate high quality data at the outset,
enabling the full potential of that data to be realized in
experimental outcomes when analyzed in software such as OMIQ and
FCS Express. Higher quality data also supports increased downstream
automation in the analysis of flow cytometry panels. The
acquisition of EasyPanel supports our commitment to deliver
reliable machine learning and AI tools for advanced automation of
flow cytometry analysis, comprising innovations that we're building
into OMIQ, FCS Express, and Dotmatics Luma."
"This is a big opportunity for EasyPanel to grow and scale our
business and help create end-to-end flow solutions together with
Dotmatics," said Omar Abouzid, co-founder and President of
EasyPanel. "Our customers and partners can expect the same level of
support from EasyPanel as they have received in the past, but now
with the benefit of having additional resources and involvement
from the Dotmatics flow cytometry team."
For more information please visit www.easypanel.ai and
www.dotmatics.com
Forward Looking Statements
This press release contains forward-looking statements that are
intended to outline our general product strategy. It is intended
for informational purposes only and speaks only as of the date the
statements are first published. It is not a commitment to deliver
any functionality and should not be relied upon for making purchase
decisions. You should not put any contractual reliance on these
statements. The development, release, and timing of any products or
capabilities remains at the sole discretion of Dotmatics.
No representation or warranty, express or implied, is provided
in relation to the fairness, accuracy, correctness, completeness or
reliability of the information, opinions or conclusions expressed
herein. Only those representations or warranties that are made in
or pursuant to one or more definitive agreements involving the
parties will have any legal effect.
About Dotmatics
Dotmatics is a leader in R&D scientific software connecting
science, data, and decision-making. Its enterprise R&D platform
and scientists' favorite applications drive efficiency and
accelerate innovation. More than 2 million scientists and 10,000
customers trust Dotmatics to help them create a healthier, cleaner,
safer world. Dotmatics is a global team of more than 800 people
dedicated to supporting its customers in over 180 countries.
Dotmatics has made 14 acquisitions since 2017. The company's
principal office is in Boston,
with 14 offices and R&D teams located around the world.
Dotmatics is backed by Insight Partners, a leading global
venture capital and private equity firm investing in high-growth
technology and software scaleup companies. Learn more about
Dotmatics, its platform, and applications including GraphPad Prism,
Geneious, SnapGene, Protein Metrics, LabArchives, OMIQ, and FCS
Express at https://www.dotmatics.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dotmatics-acquires-easypanel-to-expand-flow-cytometry-capabilities-with-advanced-panel-design-302209102.html
SOURCE Dotmatics Inc